Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Microbiome Drugs market report explains the definition, types, applications, major countries, and major players of the Microbiome Drugs market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
MicroBiome Therapeutics
Rebiotix
Ritter Pharmaceuticals
Pfizer
Enterome Bioscience
Second Genome
MaaT Pharma
OpenBiome
Seres Therapeutics
By Type:
Probiotics
Prebiotics
Small Molecules
Biological Drugs
Other
By End-User:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Other
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Microbiome Drugs Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Microbiome Drugs Outlook to 2028- Original Forecasts
-
2.2 Microbiome Drugs Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Microbiome Drugs Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Microbiome Drugs Market- Recent Developments
-
6.1 Microbiome Drugs Market News and Developments
-
6.2 Microbiome Drugs Market Deals Landscape
7 Microbiome Drugs Raw Materials and Cost Structure Analysis
-
7.1 Microbiome Drugs Key Raw Materials
-
7.2 Microbiome Drugs Price Trend of Key Raw Materials
-
7.3 Microbiome Drugs Key Suppliers of Raw Materials
-
7.4 Microbiome Drugs Market Concentration Rate of Raw Materials
-
7.5 Microbiome Drugs Cost Structure Analysis
-
7.5.1 Microbiome Drugs Raw Materials Analysis
-
7.5.2 Microbiome Drugs Labor Cost Analysis
-
7.5.3 Microbiome Drugs Manufacturing Expenses Analysis
8 Global Microbiome Drugs Import and Export Analysis (Top 10 Countries)
-
8.1 Global Microbiome Drugs Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Microbiome Drugs Export by Region (Top 10 Countries) (2017-2028)
9 Global Microbiome Drugs Market Outlook by Types and Applications to 2022
-
9.1 Global Microbiome Drugs Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Probiotics Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Prebiotics Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Small Molecules Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Biological Drugs Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Other Consumption and Growth Rate (2017-2022)
-
9.2 Global Microbiome Drugs Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospital Pharmacies Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Retail Pharmacies Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Online Pharmacies Consumption and Growth Rate (2017-2022)
-
9.2.4 Global Other Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Microbiome Drugs Market Analysis and Outlook till 2022
-
10.1 Global Microbiome Drugs Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Microbiome Drugs Consumption (2017-2022)
-
10.2.2 Canada Microbiome Drugs Consumption (2017-2022)
-
10.2.3 Mexico Microbiome Drugs Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Microbiome Drugs Consumption (2017-2022)
-
10.3.2 UK Microbiome Drugs Consumption (2017-2022)
-
10.3.3 Spain Microbiome Drugs Consumption (2017-2022)
-
10.3.4 Belgium Microbiome Drugs Consumption (2017-2022)
-
10.3.5 France Microbiome Drugs Consumption (2017-2022)
-
10.3.6 Italy Microbiome Drugs Consumption (2017-2022)
-
10.3.7 Denmark Microbiome Drugs Consumption (2017-2022)
-
10.3.8 Finland Microbiome Drugs Consumption (2017-2022)
-
10.3.9 Norway Microbiome Drugs Consumption (2017-2022)
-
10.3.10 Sweden Microbiome Drugs Consumption (2017-2022)
-
10.3.11 Poland Microbiome Drugs Consumption (2017-2022)
-
10.3.12 Russia Microbiome Drugs Consumption (2017-2022)
-
10.3.13 Turkey Microbiome Drugs Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Microbiome Drugs Consumption (2017-2022)
-
10.4.2 Japan Microbiome Drugs Consumption (2017-2022)
-
10.4.3 India Microbiome Drugs Consumption (2017-2022)
-
10.4.4 South Korea Microbiome Drugs Consumption (2017-2022)
-
10.4.5 Pakistan Microbiome Drugs Consumption (2017-2022)
-
10.4.6 Bangladesh Microbiome Drugs Consumption (2017-2022)
-
10.4.7 Indonesia Microbiome Drugs Consumption (2017-2022)
-
10.4.8 Thailand Microbiome Drugs Consumption (2017-2022)
-
10.4.9 Singapore Microbiome Drugs Consumption (2017-2022)
-
10.4.10 Malaysia Microbiome Drugs Consumption (2017-2022)
-
10.4.11 Philippines Microbiome Drugs Consumption (2017-2022)
-
10.4.12 Vietnam Microbiome Drugs Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Microbiome Drugs Consumption (2017-2022)
-
10.5.2 Colombia Microbiome Drugs Consumption (2017-2022)
-
10.5.3 Chile Microbiome Drugs Consumption (2017-2022)
-
10.5.4 Argentina Microbiome Drugs Consumption (2017-2022)
-
10.5.5 Venezuela Microbiome Drugs Consumption (2017-2022)
-
10.5.6 Peru Microbiome Drugs Consumption (2017-2022)
-
10.5.7 Puerto Rico Microbiome Drugs Consumption (2017-2022)
-
10.5.8 Ecuador Microbiome Drugs Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Microbiome Drugs Consumption (2017-2022)
-
10.6.2 Kuwait Microbiome Drugs Consumption (2017-2022)
-
10.6.3 Oman Microbiome Drugs Consumption (2017-2022)
-
10.6.4 Qatar Microbiome Drugs Consumption (2017-2022)
-
10.6.5 Saudi Arabia Microbiome Drugs Consumption (2017-2022)
-
10.6.6 United Arab Emirates Microbiome Drugs Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Microbiome Drugs Consumption (2017-2022)
-
10.7.2 South Africa Microbiome Drugs Consumption (2017-2022)
-
10.7.3 Egypt Microbiome Drugs Consumption (2017-2022)
-
10.7.4 Algeria Microbiome Drugs Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Microbiome Drugs Consumption (2017-2022)
-
10.8.2 New Zealand Microbiome Drugs Consumption (2017-2022)
11 Global Microbiome Drugs Competitive Analysis
-
11.1 MicroBiome Therapeutics
-
11.1.1 MicroBiome Therapeutics Company Details
-
11.1.2 MicroBiome Therapeutics Microbiome Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 MicroBiome Therapeutics Microbiome Drugs Main Business and Markets Served
-
11.1.4 MicroBiome Therapeutics Microbiome Drugs Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Rebiotix
-
11.2.1 Rebiotix Company Details
-
11.2.2 Rebiotix Microbiome Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Rebiotix Microbiome Drugs Main Business and Markets Served
-
11.2.4 Rebiotix Microbiome Drugs Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Ritter Pharmaceuticals
-
11.3.1 Ritter Pharmaceuticals Company Details
-
11.3.2 Ritter Pharmaceuticals Microbiome Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Ritter Pharmaceuticals Microbiome Drugs Main Business and Markets Served
-
11.3.4 Ritter Pharmaceuticals Microbiome Drugs Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Pfizer
-
11.4.1 Pfizer Company Details
-
11.4.2 Pfizer Microbiome Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Pfizer Microbiome Drugs Main Business and Markets Served
-
11.4.4 Pfizer Microbiome Drugs Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Enterome Bioscience
-
11.5.1 Enterome Bioscience Company Details
-
11.5.2 Enterome Bioscience Microbiome Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Enterome Bioscience Microbiome Drugs Main Business and Markets Served
-
11.5.4 Enterome Bioscience Microbiome Drugs Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Second Genome
-
11.6.1 Second Genome Company Details
-
11.6.2 Second Genome Microbiome Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Second Genome Microbiome Drugs Main Business and Markets Served
-
11.6.4 Second Genome Microbiome Drugs Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 MaaT Pharma
-
11.7.1 MaaT Pharma Company Details
-
11.7.2 MaaT Pharma Microbiome Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 MaaT Pharma Microbiome Drugs Main Business and Markets Served
-
11.7.4 MaaT Pharma Microbiome Drugs Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 OpenBiome
-
11.8.1 OpenBiome Company Details
-
11.8.2 OpenBiome Microbiome Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 OpenBiome Microbiome Drugs Main Business and Markets Served
-
11.8.4 OpenBiome Microbiome Drugs Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Seres Therapeutics
-
11.9.1 Seres Therapeutics Company Details
-
11.9.2 Seres Therapeutics Microbiome Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Seres Therapeutics Microbiome Drugs Main Business and Markets Served
-
11.9.4 Seres Therapeutics Microbiome Drugs Product Portfolio
-
11.9.5 Recent Research and Development Strategies
12 Global Microbiome Drugs Market Outlook by Types and Applications to 2028
-
12.1 Global Microbiome Drugs Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Probiotics Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Prebiotics Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Small Molecules Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Biological Drugs Consumption Forecast and Growth Rate (2022-2028)
-
12.1.5 Global Other Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Microbiome Drugs Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Hospital Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Retail Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Online Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
12.2.4 Global Other Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Microbiome Drugs Market Analysis and Outlook to 2028
-
13.1 Global Microbiome Drugs Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Microbiome Drugs Consumption Forecast (2022-2028)
-
13.2.2 Canada Microbiome Drugs Consumption Forecast (2022-2028)
-
13.2.3 Mexico Microbiome Drugs Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Microbiome Drugs Consumption Forecast (2022-2028)
-
13.3.2 UK Microbiome Drugs Consumption Forecast (2022-2028)
-
13.3.3 Spain Microbiome Drugs Consumption Forecast (2022-2028)
-
13.3.4 Belgium Microbiome Drugs Consumption Forecast (2022-2028)
-
13.3.5 France Microbiome Drugs Consumption Forecast (2022-2028)
-
13.3.6 Italy Microbiome Drugs Consumption Forecast (2022-2028)
-
13.3.7 Denmark Microbiome Drugs Consumption Forecast (2022-2028)
-
13.3.8 Finland Microbiome Drugs Consumption Forecast (2022-2028)
-
13.3.9 Norway Microbiome Drugs Consumption Forecast (2022-2028)
-
13.3.10 Sweden Microbiome Drugs Consumption Forecast (2022-2028)
-
13.3.11 Poland Microbiome Drugs Consumption Forecast (2022-2028)
-
13.3.12 Russia Microbiome Drugs Consumption Forecast (2022-2028)
-
13.3.13 Turkey Microbiome Drugs Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Microbiome Drugs Consumption Forecast (2022-2028)
-
13.4.2 Japan Microbiome Drugs Consumption Forecast (2022-2028)
-
13.4.3 India Microbiome Drugs Consumption Forecast (2022-2028)
-
13.4.4 South Korea Microbiome Drugs Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Microbiome Drugs Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Microbiome Drugs Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Microbiome Drugs Consumption Forecast (2022-2028)
-
13.4.8 Thailand Microbiome Drugs Consumption Forecast (2022-2028)
-
13.4.9 Singapore Microbiome Drugs Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Microbiome Drugs Consumption Forecast (2022-2028)
-
13.4.11 Philippines Microbiome Drugs Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Microbiome Drugs Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Microbiome Drugs Consumption Forecast (2022-2028)
-
13.5.2 Colombia Microbiome Drugs Consumption Forecast (2022-2028)
-
13.5.3 Chile Microbiome Drugs Consumption Forecast (2022-2028)
-
13.5.4 Argentina Microbiome Drugs Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Microbiome Drugs Consumption Forecast (2022-2028)
-
13.5.6 Peru Microbiome Drugs Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Microbiome Drugs Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Microbiome Drugs Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Microbiome Drugs Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Microbiome Drugs Consumption Forecast (2022-2028)
-
13.6.3 Oman Microbiome Drugs Consumption Forecast (2022-2028)
-
13.6.4 Qatar Microbiome Drugs Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Microbiome Drugs Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Microbiome Drugs Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Microbiome Drugs Consumption Forecast (2022-2028)
-
13.7.2 South Africa Microbiome Drugs Consumption Forecast (2022-2028)
-
13.7.3 Egypt Microbiome Drugs Consumption Forecast (2022-2028)
-
13.7.4 Algeria Microbiome Drugs Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Microbiome Drugs Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Microbiome Drugs Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Microbiome Drugs
-
Figure of Microbiome Drugs Picture
-
Table Global Microbiome Drugs Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Microbiome Drugs Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Probiotics Consumption and Growth Rate (2017-2022)
-
Figure Global Prebiotics Consumption and Growth Rate (2017-2022)
-
Figure Global Small Molecules Consumption and Growth Rate (2017-2022)
-
Figure Global Biological Drugs Consumption and Growth Rate (2017-2022)
-
Figure Global Other Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Pharmacies Consumption and Growth Rate (2017-2022)
-
Figure Global Retail Pharmacies Consumption and Growth Rate (2017-2022)
-
Figure Global Online Pharmacies Consumption and Growth Rate (2017-2022)
-
Figure Global Other Consumption and Growth Rate (2017-2022)
-
Figure Global Microbiome Drugs Consumption by Country (2017-2022)
-
Table North America Microbiome Drugs Consumption by Country (2017-2022)
-
Figure United States Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Canada Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Mexico Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Table Europe Microbiome Drugs Consumption by Country (2017-2022)
-
Figure Germany Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure UK Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Spain Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Belgium Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure France Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Italy Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Denmark Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Finland Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Norway Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Sweden Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Poland Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Russia Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Turkey Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Table APAC Microbiome Drugs Consumption by Country (2017-2022)
-
Figure China Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Japan Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure India Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Korea Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Thailand Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Singapore Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Philippines Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Table South America Microbiome Drugs Consumption by Country (2017-2022)
-
Figure Brazil Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Colombia Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Chile Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Argentina Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Peru Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Table GCC Microbiome Drugs Consumption by Country (2017-2022)
-
Figure Bahrain Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Oman Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Qatar Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Table Africa Microbiome Drugs Consumption by Country (2017-2022)
-
Figure Nigeria Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Africa Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Egypt Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure Algeria Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Table Oceania Microbiome Drugs Consumption by Country (2017-2022)
-
Figure Australia Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Microbiome Drugs Consumption and Growth Rate (2017-2022)
-
Table MicroBiome Therapeutics Company Details
-
Table MicroBiome Therapeutics Microbiome Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table MicroBiome Therapeutics Microbiome Drugs Main Business and Markets Served
-
Table MicroBiome Therapeutics Microbiome Drugs Product Portfolio
-
Table Rebiotix Company Details
-
Table Rebiotix Microbiome Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Rebiotix Microbiome Drugs Main Business and Markets Served
-
Table Rebiotix Microbiome Drugs Product Portfolio
-
Table Ritter Pharmaceuticals Company Details
-
Table Ritter Pharmaceuticals Microbiome Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Ritter Pharmaceuticals Microbiome Drugs Main Business and Markets Served
-
Table Ritter Pharmaceuticals Microbiome Drugs Product Portfolio
-
Table Pfizer Company Details
-
Table Pfizer Microbiome Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Microbiome Drugs Main Business and Markets Served
-
Table Pfizer Microbiome Drugs Product Portfolio
-
Table Enterome Bioscience Company Details
-
Table Enterome Bioscience Microbiome Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Enterome Bioscience Microbiome Drugs Main Business and Markets Served
-
Table Enterome Bioscience Microbiome Drugs Product Portfolio
-
Table Second Genome Company Details
-
Table Second Genome Microbiome Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Second Genome Microbiome Drugs Main Business and Markets Served
-
Table Second Genome Microbiome Drugs Product Portfolio
-
Table MaaT Pharma Company Details
-
Table MaaT Pharma Microbiome Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table MaaT Pharma Microbiome Drugs Main Business and Markets Served
-
Table MaaT Pharma Microbiome Drugs Product Portfolio
-
Table OpenBiome Company Details
-
Table OpenBiome Microbiome Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table OpenBiome Microbiome Drugs Main Business and Markets Served
-
Table OpenBiome Microbiome Drugs Product Portfolio
-
Table Seres Therapeutics Company Details
-
Table Seres Therapeutics Microbiome Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Seres Therapeutics Microbiome Drugs Main Business and Markets Served
-
Table Seres Therapeutics Microbiome Drugs Product Portfolio
-
Figure Global Probiotics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Prebiotics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Small Molecules Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Biological Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Other Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Retail Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Online Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Other Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Microbiome Drugs Consumption Forecast by Country (2022-2028)
-
Table North America Microbiome Drugs Consumption Forecast by Country (2022-2028)
-
Figure United States Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Microbiome Drugs Consumption Forecast by Country (2022-2028)
-
Figure Germany Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Microbiome Drugs Consumption Forecast by Country (2022-2028)
-
Figure China Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Microbiome Drugs Consumption Forecast by Country (2022-2028)
-
Figure Brazil Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Microbiome Drugs Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Microbiome Drugs Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Microbiome Drugs Consumption Forecast by Country (2022-2028)
-
Figure Australia Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Microbiome Drugs Consumption Forecast and Growth Rate (2022-2028)
-
